1. Which of the following SARS-CoV-2 variants is paired with the original parent strain in the recently authorized COVID-19 bivalent vaccine?
A. Alpha
B. Beta
C. Delta
D. Omicron
E. Unsure
2. Which of the following is true regarding the Moderna bivalent vaccine compared to the Pfizer bivalent vaccine?
A. Moderna is authorized for adults 18 years or older and Pfizer for ages 12 or older.
B. Moderna is composed of 2 separate vaccines while the Pfizer Bivalent is 1 injection.
C. Moderna is available in both an injectable and an inhaled dosage form.
D. Moderna is administered at least 3 months after the last COVID-19 injection or booster compared to 2 months for the Pfizer Bivalent vaccine.
E. Unsure
3. Which of the following is true regarding Paxlovid rebound?
A. It generally does not require retreatment.
B. It typically has been reported in unvaccinated patients.
C. Rebound symptoms are typically worse than the initial infection.
D. In the EPIC-HR rates of rebound were around 10%.
E. Unsure
4. Which of the following repurposed agents recently showed a decrease in COVID-19 hospitalizations, emergency department visits, or death?
A. Azithromycin
B. Hydroxychloroquine
C. Ivermectin
D. Metformin
E. Unsure
5. Which of the following agents has a novel mechanism of action involving microtubule filament disruption?
A. Nirmatrelvir
B. Molnupiravir
C. Sabizabulin
D. Sotrovimab
E. Unsure
6. Which of the following agents retains activity versus the currently circulating omicron subvariants, including BA.4 and BA.5, as well as the increasingly common BA.1.1?
A. Sotrovimab
B. Bebtelovimab
C. Ritonavir-boosted nirmatrelvir
D. Casirivimab
E. Unsure
7. Which of the following age groups best represents those who benefitted most from ritonavir-boosted nirmatrelvir therapy when already vaccinated?
A. 17 years of age or younger
B. 18-34 years
C. 35-64 years
D. 65 years or older
E. Unsure
8. What type of vaccine is the authorized Novavax COVID-19 product?
A. mRNA
B. DNA
C. Protein
D. Adenovirus
E. Unsure
9. In a recent single-center, real-world outcomes study of bebtelovimab, the greatest benefit of treatment was in participants with which of the following conditions?
A. Obstructive sleep apnea
B. Cardiovascular disease
C. Immunocompromised
D. Uncontrolled hypertension
E. Unsure
10. The investigational agent vilobelimab has been studied for COVID-19 in patients
A. With severe disease
B. Who were hospitalized with moderate disease
C. Who were ambulatory with moderate disease
D. With mild disease
E. Unsure
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Will the information presented cause you to change your practice?
A. Yes
B. No
21. Are you committed to making these changes?
A. Yes
B. No
22. As a result of this activity, did you learn something new?
A. Yes
B. No
23. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
24. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20